On 15th of March the EMAV members met for the first time using Zoom for an ordinary General Assembly and an EMAV Workshop.
Peter Behr, Chairman, reported that in a challenging time of business reality EMAV was able to continue the development of a mutual position regarding future rules for manufacturing of Autogenous vaccines under the harmonized legal framework of EC regulation 2019/6. At the same time the association was able to further enlarge its regional prevalence as well as the networking with stakeholders interested in the future of Autogenous vaccines.
The meeting offered the platform to take important decisions for EMAV. A real milestone was the approval of the EMAV position paper for a GMP-Annex for Autogenous vaccines to support the development of a specific GMP guidance for Autogenous vaccines.
The audience took the opportunity to re-elect Dr. Klaus-Peter Behr (Anicon/DE) as Chairman, Frans Reek (Vaxxinova/DE) as Deputy and Alain Schrumpf (Biovac-Ceva/FR) and Maarten de Gussem (Poulpharm/BE) as Board members.
In the EMAV workshop, the members learned from the presentation of Dr. Dries Minne, Head of the veterinary division of famhp/Belgium, about the decision process and timelines for Autogenous vaccines legislation based on the Regulation 2019/6/EC.
Prof. Hans-Joachim Selbitz/Germany presented an update about the status of the scientific Manual about Autogenous vaccines.
The two new EMAV members introduced their company plus informed about autogenous regulations in their country. The other EMAV members were impressed by the presentations of Dr. Pantelis Katharios of Aquatic Biologicals (Greece) and John Gilmore of FarmLab Diagnostics (Ireland).
Activity reports were presented by the EMAV expert groups too, so from Dr. Wiebke Bielenberg for the Scientific Working Group and from Maarten de Gussem for the Practice Advisory Group.